Home / Hormones & sexual health / Kisspeptin
KiHuman trials

Kisspeptin protocol

Kisspeptin is a natural brain hormone that switches on the reproductive hormone chain. It has been tested in people in research studies (injection, drip and nasal spray). It is not an approved medicine.

Not approved: no approved product found; research use onlyPhase 2 human trials exist (IVF, missed periods, delayed puberty)
ProtocolMixingResultsSide effectsHow it worksSources

The protocol at a glance

Trials dose kisspeptin-54 by body weight (nmol per kg), not as a fixed amount. Repeated twice-daily dosing made the effect fade in women with missed periods.

StudyAmount of kisspeptin-54
Human dose for general useNot established
IVF egg-maturation trigger, one shot under the skin (60 women, 2015)3.2 to 12.8 nmol per kg; later trials used 9.6 nmol per kg
Women with missed periods, under the skin twice a day for 2 weeks6.4 nmol per kg
Nasal spray, healthy adults and women with missed periods (2025)12.8 nmol per kg
Test dose into a vein, men with and without a hormone-gene disorder (2021)6.4 nmol per kg

Sources: Abbara 2015 (PMID 26192876), Jayasena 2009 (PMID 19820030), 2025 nasal study (PMID 40215751), Jayasena 2013 (PMID 24030945), 2021 men study (PMID 33227799). Kisspeptin-10 (a shorter form) was given into a vein as 0.3 mcg per kg in one dose, or 4 mcg per kg per hour as an 11-hour drip, in men with type 2 diabetes (PMID 23153270).

Community reports

Community reports commonly describe 100-200 mcg every other day.

What people say they do, collected from community discussions. Not tested in a trial; shown so you can compare it with the evidence above.

Mixing

No mixing table here: this one is used as a capsule, nasal spray or skin product, or has no human amount to calculate from. The general mixing calculator works for any vial.

What the trials found

Two human studies of kisspeptin-54 under the skin. IVF trigger, 60 women at high risk of overstimulation (Abbara 2015), and 10 women with missed periods given twice-daily shots (Jayasena 2009):

95%Women whose eggs matured after one kisspeptin shot
45%Live birth per embryo transfer (all doses)
24.0 IU/LPeak LH rise after the first shot (women with missed periods)
2.5 IU/LSame measure on day 14 - the response faded

Abbara A et al. J Clin Endocrinol Metab 2015 (PMID 26192876); Jayasena CN et al. J Clin Endocrinol Metab 2009 (PMID 19820030). The women with missed periods still responded to GnRH, so the pituitary gland still worked.

Side effects

  • The 2025 nasal-spray study reported no side effects or adverse events.
  • With repeated twice-daily shots for 2 weeks, the hormone response faded (desensitization).
  • In healthy women, 1 week of twice-daily shots did not stop cycles, but cycles got shorter on average (26.8 vs 28.6 days).
  • Long-term safety is not established.

How it works

Brain GnRH cells

Kisspeptin acts in the hypothalamus to release GnRH, which tells the pituitary gland to release LH and FSH.

Effect fades with repeats

Daily or twice-daily dosing over days to weeks reduced the response in women with missed periods.

Sources

  • Abbara A et al. J Clin Endocrinol Metab 2015, PMID 26192876
  • Abbara A et al. Hum Reprod 2017 (second dose, 62 women), PMID 28854728
  • Jayasena CN et al. J Clin Endocrinol Metab 2009, PMID 19820030
  • Jayasena CN et al. J Clin Endocrinol Metab 2013, PMID 24030945
  • Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans, EBioMedicine 2025, PMID 40215751
  • Kisspeptin-54 in men with congenital hypogonadotropic hypogonadism, Neuroendocrinology 2021, PMID 33227799
  • George JT et al. / kisspeptin-10 in men with type 2 diabetes, Clin Endocrinol 2013, PMID 23153270